Tectonic Therapeutic, Inc. (TECX) Stock Profile — Insider Trades & Financials

Net Income-$19.2M

EPS$-4.05

Market Cap$564.6M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Alise Reicin

CEO & Executive Director

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The companyâs lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Founded: 2019
Employees: 60
Headquarters: Watertown, Massachusetts, United States

⚡

Core Efficiency

ROE?

-7.65%

ROA?

-7.37%

D/E Ratio?

0.04

📊

Profitability Ratios

Current Ratio?

26.63

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Jul 15, 2026 (in 97 days)

Annual Report (10-K) — Based on filing pattern

Jul 15, 2026

Predicted10-K

Feb 26, 2026

10-KQ4 202510d after period end

Nov 6, 2025

10-QQ3 20253d after period end

Aug 7, 2025

10-QQ2 20256d after period end

May 8, 2025

10-QQ1 20257d after period end

Mar 20, 2025

10-KQ4 202419d after period end

Nov 12, 2024

10-QQ3 202411d after period end

Aug 14, 2024

10-QQ2 20245d after period end

May 9, 2024

10-QQ1 20247d after period end

Loading company sections...

Tectonic Therapeutic, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness